M&A Deal Summary

Lilly Acquires AurKa Pharma

On May 14, 2018, Lilly acquired life science company AurKa Pharma for 110M USD

Acquisition Highlights
  • This is Lilly’s 14th transaction in the Life Science sector.
  • This is Lilly’s 18th largest (disclosed) transaction.
  • This is Lilly’s 2nd transaction in Canada.
  • This is Lilly’s 2nd transaction in Quebec.

M&A Deal Summary
Date 2018-05-14
Target AurKa Pharma
Sector Life Science
Buyer(s) Lilly
Deal Type Add-on Acquisition
Deal Value 110M USD
Advisor(s) Robert W. Baird & Co., Inc. (Financial)

Target

AurKa Pharma

Montreal, Quebec, Canada
AurKa Pharma, Inc. is a developer of an oncology compound AK-01. AurKa Pharma was founded in 2016 and is based in Montreal, Quebec.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 34.1B USD (2023)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 21 of 34
Sector (Life Science) 14 of 27
Type (Add-on Acquisition) 16 of 27
State (Quebec) 2 of 2
Country (Canada) 2 of 2
Year (2018) 2 of 3
Size (of disclosed) 18 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-10 ARMO BioSciences

Redwood City, California, United States

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients, as well as earlier-Phase trials in lung cancer, liver cancer, melanoma and other solid tumor types. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).

Buy $1.6B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-14 Hydra Biosciences - Pre-Clinical Pain Program

Cambridge, Massachusetts, United States

Hydra Biosciences, Inc. - Pre-Clinical Pain Program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes.

Buy -
Mergr

Product

Company

Legal